SODIUM ACETATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for SODIUM ACETATE (SODIUM ACETATE).
Sodium acetate provides sodium ions and acetate ions. Acetate is metabolized to bicarbonate, which acts as a buffer to correct metabolic acidosis.
| Metabolism | Acetate is converted to bicarbonate via the tricarboxylic acid (TCA) cycle, primarily in the liver and muscle. |
| Excretion | Primarily renal; acetate is rapidly metabolized to bicarbonate via the Krebs cycle, with less than 5% excreted unchanged in urine. |
| Half-life | 2-3 minutes (rapid conversion to bicarbonate in circulation). Clinical context: Exogenous acetate (e.g., in parenteral nutrition) is quickly cleared, limiting duration of alkalinizing effect. |
| Protein binding | <5% (negligible); acetate is a small anion that does not significantly bind to plasma proteins. |
| Volume of Distribution | 0.4-0.6 L/kg; distributes mainly in extracellular fluid, reflecting its hydrophilic nature. |
| Bioavailability | Oral: Not applicable (used as food additive or buffer; therapeutic use is IV); IV: 100%. |
| Onset of Action | IV: Immediate (seconds to minutes) upon infusion. Oral: Rapid, within 15-30 minutes. |
| Duration of Action | 30-60 minutes after IV bolus, dose-dependent. Continuous infusion provides sustained effect as long as infused. |
| Molecular Weight | 82.03 |
Intravenous: 50-200 mL of 0.1-0.4 mEq/mL solution per dose; administer at a rate not exceeding 1 mEq/kg/hour; frequency based on serum bicarbonate and acid-base status.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-60 mL/min: Use with caution and monitor for edema, hypernatremia; GFR <30 mL/min: Avoid due to risk of volume overload and metabolic alkalosis. |
| Liver impairment | Child-Pugh Class B: Reduce dose by 25%; Child-Pugh Class C: Reduce dose by 50% or avoid due to risk of exacerbating encephalopathy. |
| Pediatric use | Neonates and children: 2-5 mEq/kg/day as a continuous infusion or divided every 6-8 hours; maximum rate 1 mEq/kg/hour; adjust based on serum electrolytes. |
| Geriatric use | Start at lower end of adult dosing; monitor for fluid overload, heart failure exacerbation, and electrolyte imbalances; consider reduced renal function. |
| 1st trimester | No known teratogenic effects. Use with caution if sodium restriction is required. |
| 2nd trimester | No known adverse fetal effects. Monitor maternal electrolyte balance. |
| 3rd trimester | Safe when used to correct metabolic acidosis. Avoid excessive sodium load in preeclampsia or fluid overload. |
Clinical note
Comprehensive clinical and safety monograph for SODIUM ACETATE (SODIUM ACETATE).
| Placental transfer | Readily crosses the placenta; levels in fetal circulation equilibrate with maternal levels. |
| Breastfeeding | Excreted into breast milk in minimal amounts. Use is considered safe; monitor infant for signs of sodium overload if maternal doses are high. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Sodium acetate is a component of parenteral nutrition and electrolyte replacement solutions. No teratogenic effects have been reported in animal studies or human pregnancy data. It is considered safe in all trimesters when used at therapeutic doses for maternal indications. There is no evidence of increased risk of fetal anomalies. |
| Fetal Monitoring | Monitor serum electrolytes (sodium, bicarbonate, chloride) and acid-base status (pH, pCO2, bicarbonate) during intravenous administration. Assess for signs of hypernatremia or metabolic alkalosis. Fetal monitoring is not routinely required unless maternal electrolyte disturbances occur. |
| Fertility Effects | Sodium acetate has no known direct effects on fertility. It does not alter reproductive function in animal studies. Indirect effects from underlying conditions requiring its use (e.g., metabolic acidosis) may affect fertility, but the drug itself is not associated with impaired fertility. |
■ FDA Black Box Warning
None.
| Serious Effects |
HypernatremiaSevere edemaCongestive heart failure (with high sodium load)Severe renal impairment with oliguria
| Precautions | Use with caution in patients with heart failure, renal impairment, or conditions that predispose to hypervolemia. Monitor serum electrolytes and acid-base balance. Rapid infusion may cause fluid overload and hypernatremia. |
| Food/Dietary | No specific food interactions known. However, dietary sodium intake should be monitored and adjusted as clinically indicated. |
| Clinical Pearls | Sodium acetate is used as a source of sodium and bicarbonate precursor in parenteral nutrition and intravenous fluids. Monitor serum sodium, bicarbonate, and acid-base status. Use with caution in patients with heart failure, hypertension, or renal impairment due to sodium load. Acetate metabolism may be impaired in severe liver disease. |
| Patient Advice | This medication is given intravenously by your healthcare provider to correct or prevent low sodium or acid-base imbalances. · Do not use extra or stop treatment without consulting your doctor. · Inform your doctor if you have heart disease, kidney problems, high blood pressure, or liver disease. · Report any swelling, shortness of breath, or irregular heartbeat. |
Loading safety data…